Registration Statement - Specified Transactions (Form S-3)

ABOUT THIS PROSPECTUS

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

PROSPECTUS SUMMARY

RISK FACTORS

USE OF PROCEEDS

SELLING STOCKHOLDERS

PLAN OF DISTRIBUTION

LEGAL MATTERS

EXPERTS

WHERE YOU CAN FIND MORE INFORMATION

INCORPORATION OF INFORMATION BY REFERENCE

Name of Selling Stockholders⁽¹⁾

Suvretta Capital Management, LLC, investment manager for entities affiliated with Averill⁽³⁾

Avoro Life Sciences Fund LLC⁽⁴⁾

Entities affiliated with Baker Bros. Advisors LP⁽⁵⁾

Atlas Private Holdings (Cayman) Ltd.⁽⁶⁾

Cormorant Global Healthcare GP, LLC, General Partner to Cormorant Global Healthcare Master Fund, LP⁽⁷⁾

Fairmount Healthcare Fund II L.P.⁽⁸⁾

Logos Opportunities Fund V LP⁽⁹⁾

RA Capital Healthcare Fund GP, LLC, General Partner of RA Capital Healthcare Fund, L.P.⁽¹⁰⁾

Columbia Management Investment Advisers, LLC, Investment Manager to Seligman Healthcare Spectrum (Master) Fund⁽¹¹⁾

Entities affiliated with Vivo Opportunity Fund⁽¹²⁾

Entities affiliated with ADAR1 Capital Management⁽¹³⁾

B Group Capital LLC⁽¹⁴⁾

Accounts managed by Caligan Partners⁽¹⁵⁾

Ikarian Capital, LLC as investment advisor to entities affiliated with Boothbay⁽¹⁶⁾

Entities affiliated with EcoR1 Capital LLC⁽¹⁹⁾

Entities affiliated with Franklin Advisers, Inc.⁽²⁰⁾

Octagon Investments Master Fund LP⁽²¹⁾

SILV Fund, Ltd.⁽²²⁾

Trails Edge Biotechnology Master Fund, LP⁽²³⁾

Woodline Master Fund LP⁽²⁴⁾

Ikarian Capital, LLC, Investment Manager to Ikarian Healthcare Master Fund, LP⁽²⁵⁾

Boxer Capital Master Fund, LP⁽²⁶⁾

Entities affiliated with Marshall Wace LLP⁽²⁷⁾

Affinity Healthcare Fund, LP⁽²⁸⁾

Alyeska Master Fund, LP⁽²⁹⁾

Entities affiliated with Special Situations Fund⁽³⁰⁾

Squadron Master Fund LP⁽³¹⁾

Able Partners NYC, LLC⁽³²⁾

Name of Selling Stockholders⁽¹⁾

Entities affiliated with AgFunder⁽³³⁾

Alpha Capital Corp.⁽³⁴⁾

Anand Parikh⁽³⁵⁾

Angelle Advisors LLC⁽³⁶⁾

Anne C. Harrison⁽³⁷⁾

Apple Island Investment Fund I⁽³⁸⁾

Bar Investments LLC⁽³⁹⁾

Benjamin D. Hopkins⁽⁴⁰⁾

Burnett F. King⁽⁴¹⁾

Cantley GRAT Remainder Trust f/b/o Alexandra Cantley u/d/t 7/1/16⁽⁴²⁾

Cantley GRAT Remainder Trust f/b/o Mariko Cantley u/d/t 7/1/16⁽⁴²⁾

Entities affiliated with Cantos Ventures⁽⁴³⁾

Entities affiliated with Consolidated Investments International Series B⁽⁴⁴⁾

Daniel J. Conway⁽⁴⁵⁾

Debbie Chirnomas⁽⁴⁶⁾

Domen Kampjut⁽⁴⁷⁾

FA-0611 Fund I, a series of Umami Capital, LP⁽⁴⁸⁾

Faeth Investments, LLC⁽⁴⁹⁾

Felix Gurevich 2023 Family Trust⁽⁵⁰⁾

Fund I, a series of Avicella Capital Fund, LP⁽⁵¹⁾

Entities affiliated with Future Ventures⁽⁵²⁾

Georgina F. Steele⁽⁵³⁾

Greg Hannon⁽⁵⁴⁾

Greg Mork⁽⁵⁵⁾

Entities affiliated with iSelect Funds⁽⁵⁶⁾

Javier Piggee⁽⁵⁷⁾

Jayson Dallas⁽⁵⁸⁾

H. Jonathan G. Lindström⁽⁵⁹⁾

Karen H. Vousden⁽⁶⁰⁾

Katelyn Patterson⁽⁶¹⁾

KdT Ventures Fund II, LP⁽⁶²⁾

Entities affiliated with Khosla Ventures⁽⁶³⁾

Lewis Cantley⁽⁶⁴⁾

Marcus Goncalves⁽⁶⁵⁾

Margao II, LP⁽⁶⁶⁾

Marina Sheyfer 2023 Family Trust⁽⁶⁷⁾

Mars Health Fund I, LLC⁽⁶⁸⁾

Oliver D.K. Maddocks⁽⁶⁹⁾

Petros A. Tyrakis⁽⁷⁰⁾

Robert Gould⁽⁷¹⁾

Ryan O'Connor⁽⁷²⁾

Ryan W. Whitney⁽⁷³⁾

S2G Builders Food & Agriculture Fund III, LP⁽⁷⁴⁾

Name of Selling Stockholders⁽¹⁾

S3 Partners Group, LLLP⁽⁷⁵⁾

Scott W. Lowe⁽⁷⁶⁾

Siddhartha Mukherjee⁽⁷⁷⁾

Simon R.V. Knott⁽⁷⁸⁾

Stephen M. Hahn⁽⁷⁹⁾

Todd A. Young⁽⁸⁰⁾

Entities affiliated with Unshackled Ventures⁽⁸¹⁾

Western Alliance Bancorp⁽⁸²⁾

Less than 1%

To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and investment power with respect to their shares of Common Stock. Unless an address is provided below, the address for the holder is 75 State Street, Suite 100, Boston, MA 02109.

"Beneficial ownership" is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person's name. The term also includes what is referred to as "indirect ownership," meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing, the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus without taking into account certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred into shares of Common Stock (i) prior to the approval of the Required Company Stockholder Matters and the Nasdaq Listing Application or (ii) if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 4.99% and 19.99%) (the "Beneficial Ownership Limitation") of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion, which Beneficial Ownership Limitation may be waived by each holder at any time following the approval by Nasdaq of the Nasdaq Listing Application and approval of the Required Company Stockholder Matters.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 1,693,082 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Averill Master Fund, Ltd. ("Averill Master"), (ii) 292,472 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Averill Madison Master Fund, Ltd. ("Averill Madison"), (iii) 29,570 shares of Common Stock held by Averill Master and (iv) 4,979 shares of Common Stock held by Averill Madison. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 1,693,082 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Averill Master in the 2026 Private Placement and the 292,472 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Averill Madison in the 2026 Private Placement. The shares reported under "Common Stock Beneficially Owned After Offering" consist of (i) 29,570 shares of Common Stock held by Averill Master (ii) 4,979 shares of Common Stock held by Averill Madison. Suvretta Capital Management, LLC ("Suvretta") is the investment manager of Averill Master and Averill Madison. Aaron Cowen is a control person of Suvretta and as such may be deemed to beneficially own these shares. Mr. Cowen disclaims beneficial ownership of all shares of Common Stock beneficially held by Averill Master and Averill Madison, other than, to the extent of any pecuniary interest therein. The address of the principal business office of Suvretta, Mr. Cowen, Averill Master and Averill Madison is 540 Madison Avenue, 7th Floor, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Averill Master and Averill Madison are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 1,444,039 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Avoro Life Sciences Fund LLC ("Avoro"), all of which were issued in the 2026 Private Placement. Avoro Capital Advisors LLC ("Avoro Capital") is the investment advisor for Avoro. Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital and may be deemed to have investment discretion and voting power over the shares held by Avoro. Dr. Aghazadeh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. The address of Avoro is 110 Greene Street, Suite 800, New York, NY 10012. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Avoro are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 1,364,936 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Baker Brothers Life Sciences, L.P. ("BBLS") and (ii) 79,103 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by 667, L.P. ("667, L.P." and together with BBLS, the "Baker Funds"), all of which were issued in the 2026 Private Placement. Baker Bros Advisors LP is the management company and investment advisor to the Baker Funds and has sole voting and investment power with respect to the shares held by the Baker Funds. Baker Bros. Advisors (GP) LLC is the sole general partner of Baker Bros. Advisors LP. Julian C. Baker and Felix J. Baker are managing members of Baker Bros. Advisors (GP) LLC. Baker Bros. Advisors (GP) LLC, Felix J. Baker, Julian C. Baker and Baker Bros. Advisors L.P. may be deemed to be beneficial owners of the securities directly held by the Baker Funds. Julian C. Baker, Felix J. Baker, Baker Bros. Advisors L.P. and Baker Bros. Advisors (GP) LLC disclaim beneficial ownership of all shares held by the Baker Funds, except to the extent of their indirect pecuniary interest therein. The business address of Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker is 860 Washington Street, 3rd Floor, New York, NY 10014. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Baker Funds are subject to a Beneficial Ownership Limitation of 4.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 902,525 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Atlas Private Holdings (Cayman) Ltd., all of which were issued in the 2026 Private Placement. Dmitry Balyasny, via intermediate entities, manages Balyasny Asset Management L.P. and has voting and investment control over the securities held by Atlas Private Holdings (Cayman) Ltd. The address for Atlas Private Holdings (Cayman) Ltd. and Balyasny Asset Management L.P. is 444 West Lake Street, 50th Floor, Chicago, IL 60606. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Atlas Private Holdings (Cayman) Ltd. are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cormorant Global Healthcare Master Fund, LP ("Cormorant"), all of which were issued in the 2026 Private Placement. Cormorant Global Healthcare GP, LLC serves as the general partner of Cormorant. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC. Each of Cormorant Global Healthcare GP, LLC and Ms. Chen disclaim beneficial ownership of such shares except to the extent of any pecuniary interest therein. Ms. Chen, as the managing member of Cormorant Global Healthcare GP, LLC, has sole voting and investment control over the shares of Common Stock held by Cormorant Global Healthcare Master Fund, LP. The address for Cormorant Global Healthcare Master Fund, LP is 200 Clarendon Street, 52nd Floor, Boston, MA 02116. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Cormorant are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Fairmount Healthcare Fund II LP ("Fairmount"), all of which were issued in the 2026 Private Placement. Fairmount Funds Management LLC

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Logos Opportunities Fund V LP ("LOF V"), all of which were issued in the 2026 Private Placement. Logos Opportunities V GP LLC ("GP V") is the general partner of Logos Opportunities Fund V LP and may be deemed to have beneficial ownership of these shares. Arsani William and Graham Walmsley are the members of GP V. Dr. William and Dr. Walmsley disclaim beneficial ownership of these securities except to the extent of each's pecuniary interest therein. The address for Logos entities is One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Logos are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by RA Capital Healthcare Fund, L.P. ("RA Capital Fund"), all of which were issued in the 2026 Private Placement. RA Capital Management, L.P. serves as an investment manager for RA Capital Fund. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the managing members. Each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by the Fund and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein and other than for purposes of determining their obligations under Section 13(d) of the Exchange Act. The principal business address of the persons and entities listed above is 200 Berkeley Street, 18th Floor, Boston, MA 02116. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by RA Capital Fund are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Seligman Healthcare Spectrum (Master) Fund ("Seligman"), all of which were issued in the 2026 Private Placement. Columbia Management Investment Advisers, LLC serves as an investment manager for Seligman. The principal business address of the persons and entities listed above is c/o Columbia Management Investment Advisors LLC 290 Congress Street, Boston, MA 02210. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Seligman are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 66,240 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Vivo Opportunity Cayman Fund, L.P. ("Vivo Cayman Fund") and (ii) 655,780 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Vivo Opportunity Fund Holdings, L.P. ("Vivo Opportunity Fund" and together with Vivo Cayman Fund, the "Vivo Funds"), all of which were issued in the 2026 Private Placement. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund. Vivo Opportunity

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 314,079 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by ADAR1 Partners, LP ("ADAR1") and (ii) 46,931 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Spearhead Insurance Solutions IDF, LLC-Series ADAR1 ("Spearhead", and together with ADAR1, the "ADAR1 Funds"), all of which were issued in the 2026 Private Placement. The investment manager of ADAR1 and the sub-adviser of Spearhead is ADAR1 Capital Management, LLC. The general partner of ADAR1 is ADAR1 Capital Management GP, LLC. The manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC is Daniel Schneeberger. This individual may be deemed to have shared voting and investment power of the shares held by the ADAR1 Funds. This individual disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address for ADAR1 and Daniel Schneeberger is 3503 Wild Cherry Drive, Building 9, Austin, TX 78738. The address for Spearhead is 3828 Kennett Pike, Suite 202, Greenville, DE 19807. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the ADAR1 Funds are subject to a Beneficial Ownership Limitation of 4.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by B Group Capital LLC issued to B Group Capital LLC in the 2026 Private Placement and (ii) 249,159 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by B Group Capital LLC issued to B Group Capital LLC in the Acquisition. Branden B. Muhl as the manager of B Group Capital LLC has the power to vote and dispose of the securities held by B Group Capital LLC. The principal business address of these persons and entities is 2900 McKinnon St. Suite 1101, Dallas, TX 75201. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by B Group Capital LLC are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 281,120 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Caligan Partners Master Fund LP ("Caligan Fund"), (ii) 79,890 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by certain accounts managed by Caligan (the "Managed Accounts") (iii) 98,343 shares of Common Stock held by Caligan Fund and (iv) 27,659 shares of Common Stock held by the Managed Accounts. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 281,120 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Caligan Fund and 79,890 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to the Managed Accounts in the 2026 Private Placement. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 98,343 shares of Common Stock held by Caligan Fund and 27,659 shares of Common Stock held by the Managed Accounts. Caligan Partners LP ("Caligan") serves indirectly as the investment manager to the Caligan Fund and the Managed Accounts. David Johnson is the Managing Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan, and may be deemed to have voting and investment power over the securities beneficially owned by Caligan and Caligan Fund. The address of the foregoing entities and person is 780 Third Avenue, 30th Floor, New York, New York 10017. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Caligan Fund and the Managed Accounts are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 20,999 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by

[Reserved.]

[Reserved.]

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 23,357 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by EcoR1 Capital Fund, L.P. ("EcoR1 Capital Fund") and (ii) 337,653 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by EcoR1 Capital Fund Qualified, L.P. ("EcoR1 Qualified Fund", together with the EcoR1 Capital Fund, the "EcoR1 Funds"), all of which were issued in the 2026 Private Placement. EcoR1 Capital, LLC ("EcoR1") is the general partner of the EcoR1 Funds. Oleg Nodelman is the control person of EcoR1 and may be deemed to share dispositive and voting power over the shares held by the EcoR1 Funds. Mr. Nodelman and EcoR1 both disclaim beneficial ownership of all shares except to the extent of their pecuniary interest therein. The address of the above persons is 357 Tehama Street #3, San Francisco, CA 94103. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the EcoR1 Funds are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 131,940 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Franklin Strategic Series-Franklin Biotechnology Discovery Fund ("Franklin Strategic"), (ii) 229,070 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Franklin Templeton Investment Funds-Franklin Biotechnology Discovery Fund ("Franklin Templeton"), (iii) 48,771 shares of Common Stock held by Franklin Strategic and (iv) 84,721 shares of Common Stock held by Franklin Templeton. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 131,940 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Franklin Strategic in the 2026 Private Placement and the 229,070 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Franklin Templeton in the 2026 Private Placement. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 48,771 shares of Common Stock held by Franklin Strategic and 84,721 shares of Common Stock held by Franklin Templeton. Franklin Advisers, Inc., an SEC registered broker-dealer, is the investment adviser to both Franklin Strategic and Franklin Templeton. Evan McCulloch is the portfolio manager for both Franklin Strategic and Franklin Templeton. Mr. McCulloch may be deemed to have voting and investment power over the securities held by Franklin Strategic and Franklin Templeton. The address of Franklin Strategic is c/o Franklin Advisers, Inc., One Franklin Parkway, San Mateo, CA 94403. The address of Franklin Templeton is 8A Rue Albert Borschette, 1246 Kirchberg, Luxembourg. The shares of Common

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Octagon Investments Master Fund LP ("Octagon"), all of which were issued in the 2026 Private Placement. Octagon Capital Advisors LP is the Investment Manager of Octagon Investments Master Fund LP. Ting Jia, Ph.D. is the founder, managing member and Chief Investment Officer of Octagon Capital Advisors LP. By virtue of such relationships, Dr. Jia and Octagon Capital Advisors LP may be deemed to have voting and investment power of the shares held by Octagon Investments Master Fund LP. Each of Dr. Jia and Octagon Capital Advisors LP disclaims beneficial ownership of the shares held by Octagon Investments Master Fund LP, except to the extent of his or its pecuniary interest therein, if any. The address for each of Dr. Jia, Octagon Capital Advisors LP and Octagon Investments Master Fund LP is 654 Madison Avenue, 21st Floor, New York, NY 10065. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Octagon are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by SILV Fund, Ltd. ("SILV Fund"), all of which were issued in the 2026 Private Placement. Sirenia Capital Management LP ("Sirenia") has investment and voting power with respect to the securities held by certain investment funds it manages, including SILV Fund. Sirenia Capital Management GP LLC ("Sirenia GP") is the general partner of Sirenia. Alex Silverstein is the managing member of Sirenia GP. Each of SILV Fund, Sirenia GP and Mr. Silverstein disclaim beneficial ownership over such securities. The business address for the individual and entities referenced in this footnote is c/o Sirenia Capital Management LP, 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by SILV Fund are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Trails Edge Biotechnology Master Fund, LP ("Trails Edge Biotechnology") and (ii) 125,000 shares of Common Stock held by Trails Edge Biotechnology. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Trails Edge Biotechnology in the 2026 Private Placement. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 125,000 shares of Common Stock held by Trails Edge Biotechnology. Trails Edge Capital Partners, LP ("Trails Edge Capital") is the investment manager to Trails Edge Biotechnology and may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own such securities. The address of these funds and persons is 3445 Peachtree Road NE, Atlanta, GA 30326. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Trails Edge Biotechnology are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Woodline Master Fund LP ("Woodline"). The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Woodline in the 2026 Private Placement. Woodline Partners LP serves as the investment manager of Woodline and may be deemed to be the beneficial owner of the shares. Woodline Partners LP disclaims any beneficial ownership of these shares. The address of Woodline is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Woodline are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 204,225 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Ikarian Healthcare Master Fund, LP ("Ikarian"), (ii) 5,076 shares of Common Stock held by Ikarian, and does not include the shares reported in Footnote (16). The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 204,225 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Ikarian in the 2026 Private Placement. Neil Shahrestani may be deemed to be the beneficial owner of the shares held by Ikarian and disclaims such beneficial ownership of the shares held by Ikarian, except to the extent of his pecuniary interest therein if any. The address for Ikarian is 100 Crescent Ct., Suite 1620, Dallas, TX 75201. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Ikarian are subject to a Beneficial Ownership Limitation of 4.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 180,505 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Boxer Capital Master Fund, LP ("Boxer Fund"), all of which were issued in the 2026 Private Placement. Aaron Davis has voting and dispositive power over the securities held by Boxer Fund. The address of Boxer Fund is 12860 El Camino Real, Ste 300 San Diego, CA 92130. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Boxer Fund are subject to a Beneficial Ownership Limitation of 4.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 150,421 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Marshall Wace Investment Strategies-Eureka Fund ("Eureka Fund"), (ii) 30,084 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by MW XO Health Innovations Fund II ("MW XO") and (iii) 37,529 shares of Common Stock held by Eureka Fund. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 150,421 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Eureka Fund in the 2026 Private Placement and the 30,084 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to MW XO in the 2026 Private Placement. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 37,529 shares of Common Stock held by the Eureka Fund. Marshall Wace LLP is the investment manager to the Eureka Fund. Marshall Wace North America L.P. is the investment manager to MW XO. The address of the foregoing entities is George House, 131 Sloane Street, London, SW1X 9AT. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Eureka Fund and MW XO are subject to a Beneficial Ownership Limitation of 4.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 144,404 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Affinity Healthcare Fund L.P., all of which were issued in the 2026 Private Placement. Affinity Asset Advisors, LLC is the investment manager of Affinity Healthcare Fund L.P., and Michael Cho may be deemed to indirectly beneficially own the securities directly held by Affinity Healthcare Fund L.P. The address of Affinity Healthcare Fund L.P., Affinity Asset Advisors, LLC and Mr. Cho is 450 Park Avenue, Suite 1403, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Affinity Healthcare Fund L.P. are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 144,404 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Alyeska Master Fund, L.P. ("Alyeska Master Fund"), all of which were issued in the 2026 Private Placement. Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund (the "Selling Securityholder"), has voting and investment control of the shares held by the Selling Securityholder. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr. Parekh, however, disclaims any beneficial ownership of the shares held by the Selling Securityholder. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, KY1-1104, Cayman Islands.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 18,050 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Special Situations Life Sciences Fund, L.P. ("SS Life Sciences"), (ii) 41,929 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Special Situations Fund III QP, L.P. ("SS QP"), (iii) 12,222 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Special Situations Cayman Fund, L.P. ("SS Cayman" and, together with SS Life Sciences and SS QP, the "Special Situations Funds"), (iv) 211 shares of Common Stock held by SS Life Sciences, (v) 487 shares of Common Stock held by SS QP and (vi) 145 shares of Common Stock held by SS Cayman. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 18,050 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to SS Life Sciences in the 2026 Private Placement, the 41,929 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to SS QP in the 2026 Private Placement and the 12,222 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to SS Cayman in the 2026 Private Placement. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 211 shares of Common Stock held by SS Life Sciences, 487 shares of Common Stock held by SS QP and 145 shares of Common Stock held by SS Cayman. A WM Investment Company, Inc. ("A WM") is the investment adviser to each of the Special Situations Funds. David Greenhouse and Adam Stettner are the principal owners of A WM. Through their control of A WM, Messrs. Greenhouse and Stettner share voting and investment control over the portfolio securities of each of the Special Situations Funds. Messrs. Greenhouse and Stettner disclaim any beneficial ownership of the reported shares other than to the extent of any pecuniary interest each of them may have therein. The address of AWM, each of the Special Situations Funds and Messrs. Greenhouse and Stettner is 527 Madison Avenue, Suite 2600, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Special Situations Funds are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 72,201 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Squadron Master Fund LP, all of which were issued in the 2026 Private Placement. Squadron Capital Management LLC serves as investment adviser to Squadron Master Fund LP and may be deemed to be the beneficial owner of all securities held by the fund. Matthew Sesterhenn and William F. Blank III, as Partners of Squadron Capital Management LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all securities held by the funds. Squadron Capital Management LLC and Messrs. Sesterhenn and Blank disclaim beneficial ownership over any of the securities. The address of Squadron Capital Management LLC is 999 Oakmont Plaza Drive, Suite 600, Westmont, IL 60559. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Squadron Master Fund LP are subject to a Beneficial Ownership Limitation of 9.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 9,176 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Able Partners NYC, LLC ("Able Partners"), all of which were issued in the Acquisition. Lisa Blau may be deemed to be beneficial owner of securities held by Able Partners. The address for Able Partners is 30 Hudson Yards, FL 72, New York, NY 10001. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Able Partners are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 1,861 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by AgFunder Fund IV, L.P. ("AgFunder IV") and (ii) 2,287 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by AgFunder Co-Investment Fund III, A Series of AgFunder Master Fund, LLC ("AgFunder Co-Investment"), all of which were issued in the Acquisition. Donald Rob Leclerc may be deemed to have

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 62,264 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Alpha Capital Corp., all of which were issued in the Acquisition. Jaime Javier Montealegre may be deemed to be beneficial owner of securities held by Alpha Capital Corp. The address for Alpha Capital Corp. is c/o Fox Horan & Camerini LLP (RUB/ABF) 885 Third Avenue, Floor 17, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Alpha Capital Corp. are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 761,428 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Anand Parikh and (ii) 42,933 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 761,428 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Mr. Parikh in the Acquisition. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 42,933 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr. Parikh are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 18,679 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Angelle Advisors LLC, all of which were issued in the Acquisition. Chris Wang serves as the controlling person of Angelle Advisors LLC and may be deemed to have investment discretion and voting power over the shares held by Angelle Advisors LLC. The address for Angelle Advisors LLC is 5348 Vegas Drive, Suite 947, Las Vegas, NV 89108. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Angelle Advisors LLC are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 12,453 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Anne C. Harrison, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Anne C. Harrison are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 18,352 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Apple Island Investment Fund I LLC ("Apple Island"), all of which were issued in the Acquisition. Sachin Gupta serves as the controlling person of Apple Island and may be deemed to have investment discretion and voting power over the shares held by Apple Island. The address for Apple Island is 820 S. Washington, Hinsdale, IL 60521. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Apple Island are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 13,698 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Bar Investments LLC, all of which were issued in the Acquisition. Prashanth Reddy serves as the controlling person of Bar Investments LLC and may be deemed to have investment discretion and voting power over the shares held by Bar Investments LLC. The address for Bar Investments LLC is 700 E Ogden, Suite 305, Westmont, IL 60559. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Bar Investments LLC are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Benjamin D. Hopkins, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Benjamin D. Hopkins are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 4,980 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Burnett F. King, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Burnett F. King are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 26,577 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantley GRAT Remainder Trust f/b/o Alexandra Cantley u/d/t 7/1/16 ("A. Cantley Trust") and (ii) 26,577 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantley GRAT Remainder Trust f/b/o Mariko Cantley u/d/t 7/1/16 ("M. Cantley Trust"), all of which were issued in the Acquisition. Vicki Sato may be deemed to have investment discretion and voting power over the shares held by the A. Cantley Trust and the M. Cantley Trust. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the A. Cantley Trust and the M. Cantley Trust are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consists of (i) 18,608 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantos Ivy, L.L.C. ("Cantos Ivy"), (ii) 118,207 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantos Ventures III, L.P. ("Cantos Ventures") and (iii) 8,737 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by FA Fund I, a series of Cantos Ventures Funds, LP ("FA Fund"), all of which were issued in the Acquisition. Julian Rountree may be deemed to have investment discretion and voting power over the shares held by Cantos Ivy, Cantos Ventures and FA Fund. The address for Cantos Ivy and Cantos Ventures is 595 Pacific Ave, 4th Floor, San Francisco, CA 94133. The address for FA Fund is PO Box 3217, Seattle, WA 98114. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Cantos Ivy, Cantos Ventures and FA Fund are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 18,608 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Consolidated Investments International, LLC Series B ("Consolidated Investments Series B") and (ii) 124,527 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Consolidated Investments International, LLC Series G ("Consolidated Investments Series G"), all of which were issued in the Acquisition. Robert Granieri serves as the sole member of each of Consolidated Investments Series B and Consolidated Investments Series G and may be deemed to have investment discretion and voting power over the shares held by Consolidated Investments Series B and Consolidated Investments Series G. The address for Consolidated Investments Series B and Consolidated Investments Series G is 500 Mamaroneck Avenue, Suite 301, Harrison, NY 10528. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Consolidated Investments Series B and Consolidated Investments Series G are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 2,972 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Daniel J. Conway, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Daniel J. Conway are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 156,669 shares of Common Stock issuable

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consist of (i) 1,016 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Domen Kampjut and (ii) 1,594 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 1,016 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Domen Kampjut in the Acquisition. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 1,594 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Domen Kampjut are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 27,262 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by FA-0611 Fund I, a series of Umami Capital, LP ("FA-0611"), all of which were issued in the Acquisition. James Lu Morrissey serves as the controlling person of FA-0611 and may be deemed to have investment discretion and voting power over the shares held by FA-0611. Mr. Morrissey disclaims beneficial ownership of these shares. The address for FA-0611 is PO Box 3217, Seattle, WA 98114. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by FA-0611 are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 124,527 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Faeth Investments, LLC, all of which were issued in the Acquisition. Rodney H. Thomas may be deemed to be beneficial owner of securities held by Faeth Investments, LLC. The address for Faeth Investments, LLC is 12647 Olive Blvd, Ste. 510, St. Louis, MO 63141. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Faeth Investments, LLC are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 39,849 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by the Felix Gurevich 2023 Family Trust (the "Gurevich Trust"), all of which were issued in the Acquisition. Does not include the shares reported in Footnote (67). Felix Gurevich serves as the controlling person of the Gurevich Trust and may be deemed to have investment discretion and voting power over the shares held by the Gurevich Trust. The address for the Gurevich Trust is 17305 Ponte Chiasso Dr., Boca Raton, FL 33496. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Gurevich Trust are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 249,053 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Fund I, a series of Avicella Capital Fund, LP ("Avicella Fund I"), all of which were issued in the Acquisition. Gennady Bratslavsky serves as the controlling person of Avicella Fund I and may be deemed to have investment discretion and voting power over the shares held by Avicella Fund I. Mr. Bratslavsky disclaims beneficial ownership of these shares. The address for Fund I is PO Box 3217, Seattle, WA 98114. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Avicella Fund I are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 955,468 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Future Ventures L.P. ("Future Ventures") and (ii) 60,987 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Future Ventures Side Fund, L.P. ("Future Side Fund"), all of which were issued in

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 94 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Georgina F. Steele, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Georgina F. Steele are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Greg Hannon, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr. Hannon are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 13,516 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Greg Mork, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr. Mork are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 32,227 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by iSelect Qualified Purchaser Fund, LLC ("iSelect Purchaser") and (ii) 13,330 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by iSelect Innovation Fund (B) I, LLC ("iSelect Innovation"), all of which were issued in the Acquisition. James Carter Williams serves as the controlling person of iSelect Purchaser and iSelect Innovation and may be deemed to have investment discretion and voting power over the shares held by iSelect Purchaser and iSelect Innovation. The address for iSelect Purchaser and iSelect Innovation is 7750 Maryland Avenue, Box 11826, St. Louis, MO 63105. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by iSelect Purchaser and iSelect Innovation are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 3,320 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Javier Piggee, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr. Piggee are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 44,763 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Jayson Dallas, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr. Dallas are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consists of (i) 100 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by H. Jonathan G. Lindström and (ii) 3,321 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 100 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Mr. Lindström in the Acquisition. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 3,321 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr. Lindström are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Karen H. Vousden, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Karen H. Vousden are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 623 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Katelyn M. Patterson, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Katelyn M. Patterson are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 114,885 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by KdT Ventures Fund II, LP ("KdT Ventures"), all of which were issued in the Acquisition. Mack Healy may be deemed to be beneficial owner of securities held by KdT Ventures. The address for KdT Ventures is 910 Juniper St., Austin, TX 78702. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by KdT Ventures are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consists of (i) 988,883 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Khosla Ventures Series D, LP ("KV Seed D LP") and (ii) 1,643,349 shares of Common Stock issuable upon conversion of Series B Preferred Stock held by Khosla Ventures VI, LP ("KV VI LP", and, together with KV Seed D LP, "Khosla Ventures"), all of which were issued in the Acquisition. Khosla Ventures Seed Associates D, LLC ("KV Seed D GP") is the general partner of KV Seed D LP. Khosla Ventures Associates VI, LLC ("KV VI GP") is the general partner of KV VI LP. Vinod Khosla is the managing member of VK Services, LLC ("VK Services"), which is the sole manager of each of KV Seed GP and KV VI GP. Each of KV Seed D GP, VK Services and Vinod Khosla may be deemed to possess voting and investment control over such securities held by KV Seed D LP, and each of KV Seed D GP, VK Services, and Vinod Khosla may be deemed to have indirect beneficial ownership of such securities held by KV Seed D LP. Each of KV VI GP, VK Services and Vinod Khosla may be deemed to possess voting and investment control over such securities held by KV VI LP, and each of KV VI GP, VK Services, and Vinod Khosla may be deemed to have indirect beneficial ownership of such securities held by KV VI LP. Each reporting person disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interests therein. The address for each entity is 2128 Sand Hill Road, Menlo Park, CA 94025. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Khosla Ventures are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consists of 26,578 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Lewis Cantley, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Lewis Cantley are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Marcus Goncalves, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Marcus Goncalves are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 18,679 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Margao II, LP ("Margao II"), all of which were issued in the Acquisition. Mark Britto may be deemed to be beneficial owner of securities held by Margao II. The address for Margao is 2800 Warren St., Austin, TX 78703. The shares of Common Stock

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 59,773 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by the Marina Sheyfer 2023 Family Trust (the "Sheyfer Trust"), all of which were issued in the Acquisition. Does not include the shares reported in Footnote (50). Felix Gurevich serves as the controlling person of the Sheyfer Trust and may be deemed to have investment discretion and voting power over the shares held by the Sheyfer Trust. The address for the Sheyfer Trust is 17305 Ponte Chiasso Dr., Boca Raton, FL 33496. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Sheyfer Trust are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 223,818 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Mars Health Fund I, LLC ("Mars"), all of which were issued in the Acquisition. Geoffrey W. Smith may be deemed to be beneficial owner of securities held by Mars. The address for Mars is 11 Times Square, Suite 1500A, New York, NY 10036. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mars are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 458,927 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Oliver D.K. Maddocks, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Oliver D.K. Maddocks are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" consists of (i) 1,862 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Petros A. Tyrakis and (ii) 4,273 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares reported under "Common Stock That May Be Offered Pursuant to the Prospectus" consist of the 1,862 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Petros A. Tyrakis in the Acquisition. The shares reported under "Common Stock Beneficially Owned After Offering" consist of 4,273 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March 31, 2026. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Petros A. Tyrakis are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 27,783 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Robert Gould, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Robert Gould are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 262 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Ryan O'Connor, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Ryan O'Connor are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 14,237 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Ryan W. Whitney, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Ryan W. Whitney are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 2,919,672 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by S2G Builders Food & Agriculture

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 18,352 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by S3 Partners Group, LLLP ("S3 Partners"), all of which were issued in the Acquisition. J. Brock Saunders may be deemed to be beneficial owner of securities held by S3 Partners. The address for S3 Partners is 5605 Grove Ave., Richmond, VA 23226. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by S3 Partners are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Scott W. Lowe, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Scott W. Lowe are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 119,597 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Siddhartha Mukherjee, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Siddhartha Mukherjee are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Simon R.V. Knott, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Simon R.V. Knott are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 44,763 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Stephen M. Hahn, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Stephen M. Hahn are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 7,915 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Todd A. Young, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Todd A. Young are subject to a Beneficial Ownership Limitation of 19.99%.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of (i) 2,280 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Ventures Fund II, LP ("Unshackled Ventures II"), (ii) 1,226 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Ventures Fund II-A, LP ("Unshackled Fund II-A"), (iii) 24,906 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Syndicate 2018, LLC ("Unshackled Syndicate") and (iv) 7,444 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Syndicate 2018 LLC (Class E- Faeth) ("Unshackled Syndicate Class E", and together with Unshackled Ventures II, Unshackled Ventures II-A, and Unshackled Syndicate, the "Unshackled Funds"), all of which were issued in the Acquisition. ANAR Management, LLC. serves as an investment manager for Unshackled Funds, of which Manan Mehta and Nitin Pachisia are the controlling persons. Each such person may be deemed as the beneficial owner of such shares, and each such person, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein and other than for purposes of determining their obligations under Section 13(d) of the Exchange Act.

The shares reported under "Shares of Common Stock Beneficially Owned Prior to Offering" and "Common Stock That May Be Offered Pursuant to the Prospectus" consist of 2,102 shares of Common Stock issuable upon exercise of the Warrant held by Western Alliance Bancorp ("Western Alliance") to purchase shares of Series B Preferred Stock, which will be exercisable for shares of Common Stock upon conversion of the shares of Series B Preferred Stock. The Warrant was assumed by the Company in the Acquisition. The address for Western Alliance is One E. Washington, Suite 1400, Phoenix, AZ 85004. The shares of Common Stock underlying the shares of Series B Preferred Stock issuable upon exercise of the Warrant held by Western Alliance are subject to a Beneficial Ownership Limitation of 19.99%.

Following the Acquisition, Anand Parikh was appointed as our Chief Operating Officer. In addition, Mr. Parikh is a co-founder of Faeth and previously served as the Chief Executive Officer and a director of Faeth Subsidiary from April 2019 until the closing of the Acquisition.

Oliver Maddocks is a co-founder of Faeth has served as the Chief Scientific Officer of Faeth Subsidiary since April 2019. In addition, Mr. Maddocks previously served as a director of Faeth Subsidiary from April 2019 until the closing of the Acquisition.

Debbie Chirnomas has served as the Chief Medical Officer of Faeth Subsidiary since May 2023.

Each of Benjamin D. Hopkins, Greg Hannon, Marcus Goncalves, Lewis Cantley, Karen Vousden, Siddhartha Mukherjee and Scott W. Lowe is a scientific co-founder of Faeth.

We expect that Karen Vousden will be appointed as a member of our board of directors following the receipt of stockholder approval of the Required Company Stockholder Matters.

Stephen M. Hahn previously served as a director of Faeth Subsidiary from September 2024 until the closing of the Acquisition. In addition, we expect that Mr. Hahn will be appointed as a member of our board of directors following the receipt of stockholder approval of the Required Company Stockholder Matters.

Jayson Dallas previously served as a director of Faeth Subsidiary from June 2024 until the closing of the Acquisition.

Robert Gould previously served as a director of Faeth Subsidiary from July 2021 until the closing of the Acquisition.

A designee of Khosla Ventures previously served on the board of directors of Faeth Subsidiary from June 2019 until the closing of the Acquisition pursuant to Khosla Ventures' previously held right to designate a director to the board of directors of Faeth Subsidiary.

A designee of S2G Fund previously served on the board of directors of Faeth Subsidiary from March 2022 until June 2024 pursuant to S2G Fund's previously held right to designate a director to the board of directors of Faeth Subsidiary.

Ryan W. Whitney previously served as the Chief of Staff and VP and Head of Finance, Operations of Faeth Subsidiary from January 2020 to June 2025.

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

an exchange distribution in accordance with the rules of the applicable exchange;

privately negotiated transactions;

short sales and settlement of short sales;

through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;

a combination of any such methods of sale; and

any other method permitted pursuant to applicable law.

our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 30, 2026;

our Definitive Proxy Statement on Schedule 14A for our Annual Meeting filed with the SEC on April 27, 2026 (except for information contained therein which is furnished rather than filed);

our Current Reports on Form 8-K (except for information contained therein which is furnished rather than filed) filed on February 13, 2026, February 18, 2026 (as amended on April 15, 2026), and April 16, 2026; and

the description of our Common Stock which is registered under Section 12 of the Exchange Act, described in Exhibit 4.1 to our Annual Report for the fiscal year ended December 31, 2025, filed with the SEC on March 30, 2026, including all amendments or reports filed for the purpose of updating such description.

Other Expenses of Issuance and Distribution

SEC registration fee

Printing and engraving

Legal fees and expenses

Accounting fees and expenses

Miscellaneous expenses

Total

Indemnification of Officers and Directors

Exhibits

Exhibit

Number

Description

Exhibit

Number

Description

Filed herewith.

Certain schedules, annexes and attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to provide, on a supplemental basis, a copy of any omitted schedules, annexes and attachments to the SEC or its staff upon request.

Undertakings

Signature

Title

Date

/s/ Christopher W. Gerry

Christopher W. Gerry

President, General Counsel and Director (Principal Executive Officer)

/s/ Josiah Craver

Josiah Craver

Senior Vice President of Finance

(Principal Financial Officer and Principal Accounting Officer)

/s/ Bob Holmen

Bob Holmen

Director

/s/ Thomas Ricks

Thomas Ricks

Director

/s/ Kristian Humer

Kristian Humer

Director

Signature

Title

Date

/s/ Phillip Donenberg

Phillip Donenberg

Director

/s/ Anand Parikh

Anand Parikh

Director